FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™)
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 365 (1) , 95-107
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Methoxychalcone inhibitors of androgen receptor translocation and functionBioorganic & Medicinal Chemistry Letters, 2012
- Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver CancerCell, 2012
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancerThe EMBO Journal, 2011
- Extensive chromatin remodelling and establishment of transcription factor ‘hotspots’ during early adipogenesisThe EMBO Journal, 2011
- Chromatin accessibility pre-determines glucocorticoid receptor binding patternsNature Genetics, 2011
- FOXA1 is a key determinant of estrogen receptor function and endocrine responseNature Genetics, 2010
- The FoxA factors in organogenesis and differentiationCurrent Opinion in Genetics & Development, 2010
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate CancerCell, 2009
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008